Video Experimental Relacionado
Updated: Aug 11, 2025
09:38
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
Un panel farmacogenético de 12 genes para prevenir las reacciones adversas a los fármacos: un estudio abierto,
Jesse J Swen1, Cathelijne H van der Wouden1, Lisanne En Manson1
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, Netherlands.
Lancet (London, England)
|February 4, 2023
Resumen
Las pruebas farmacogenéticas preventivas con un panel de 12 genes redujeron significativamente las reacciones adversas a los medicamentos en un gran estudio europeo. Este enfoque guiado por genotipo demostró viabilidad en diversos entornos de atención médica, mejorando la seguridad de la terapia farmacológica.
Área de la Ciencia:
- Farmacogenómica
- Farmacología clínica
- La genética
Sus antecedentes:
- Los beneficios de las pruebas farmacogenéticas son conocidos para los pares de fármacos de un solo gen.
- La utilidad clínica de los paneles de genotipado preventivo requiere una evaluación rigurosa.
Objetivo del estudio:
- Evaluar la utilidad clínica de un panel farmacogenético de 12 genes para el genotipado preventivo.
- Evaluar el impacto del tratamiento guiado por genotipo en las reacciones adversas a los medicamentos.
Principales métodos:
- Estudio de aplicación abierto, multicéntrico, controlado, aleatorizado por clúster y cruzado en 18 hospitales, 9 centros de salud y 28 farmacias de 7 países europeos.
- Genotipado de panel farmacogenético de 12 genes para 50 variantes de la línea germinal en pacientes que reciben una primera receta para un fármaco índice.
- Comparación del tratamiento guiado por genotipo (siguiendo las recomendaciones del Grupo de Trabajo Holandés de Farmacogenética para las variantes procesables) frente a la atención estándar.
- Resultado primario: reacciones adversas clínicamente relevantes dentro de las 12 semanas.
Principales resultados:
- Se incluyeron 6944 pacientes; 3342 en el grupo guiado por genotipo, 3602 en el grupo de tratamiento estándar.
- En los pacientes con resultados procesables, las reacciones adversas se produjeron en el 21,0% (estudio) frente al 27,7% (control) (OR 0,70; p=0,0075).
- En todos los pacientes, la incidencia fue del 21,5% (estudio) frente al 28,6% (control) (OR 0,70; p < 0, 0001).
Conclusiones:
- El tratamiento guiado por genotipo con un panel farmacogenético de 12 genes redujo significativamente las reacciones adversas al medicamento.
- La estrategia es factible en los diversos sistemas de salud europeos.
- La aplicación a gran escala puede mejorar la seguridad de la terapia farmacológica.
Videos de Conceptos Relacionados
01:19Pharmacovigilance
938
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
938
01:21Factors Affecting Drug Response: Overview
2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
01:12Analysis of Population Pharmacokinetic Data
331
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
331
01:11Genome-wide Association Studies-GWAS
13.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.8K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
90
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
90